LGND (Ligand Pharmaceuticals Inc.) Stock Analysis - Analyst Ratings

Ligand Pharmaceuticals Inc. (LGND) is a publicly traded Healthcare sector company. As of May 21, 2026, LGND trades at $217.75 with a market cap of $4.17B and a P/E ratio of 27.80. LGND moved +4.88% today. Year to date, LGND is +13.39%; over the trailing twelve months it is +107.54%. Its 52-week range spans $93.58 to $247.38. Analyst consensus is strong buy with an average price target of $279.71. Rallies surfaces LGND's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate LGND?

7 analysts cover LGND: 0 strong buy, 7 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $279.71.

LGND Key Metrics

Key financial metrics for LGND
MetricValue
Price$217.75
Market Cap$4.17B
P/E Ratio27.80
EPS$7.90
Dividend Yield0.08%
52-Week High$247.38
52-Week Low$93.58
Volume0
Avg Volume0
Revenue (TTM)$274.48M
Net Income$153.56M
Gross Margin0.00%

LGND Analyst Consensus

7 analysts cover LGND: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $279.71.

Latest LGND News

Recent LGND Insider Trades

  • KOZARICH JOHN W sold 1.57K (~$352.01K) on May 13, 2026.
  • KOZARICH JOHN W sold 459 (~$102.82K) on May 12, 2026.
  • KOZARICH JOHN W sold 80 (~$18.19K) on May 1, 2026.

Common questions about LGND

What do analysts rate LGND?
7 analysts cover LGND: 0 strong buy, 7 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $279.71.
Does Rallies show LGND price targets?
Yes. Rallies tracks LGND analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is LGND research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LGND. It does not provide personalized investment advice.
LGND

LGND